Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 repeat-dose sibeprenlimab in pediatric IgA nephropathy
jRCT2071260082Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Efficacy: change in urine protein-creatinine ratio, Pharmacokinetics: sibeprenlimab serum concentration and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2071260082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260082.